Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930044 · ClinicalTrials.gov registry record · NA
Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02930044 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 18 participants.
The verdict
NCT02930044, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether adult DKA patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous (IV) insulin infusion.
Interventions
- OTHER Early administration of subcutaneous insulin glargine dose
- OTHER IV insulin infusion
- DRUG IV fluid repletion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930044
The ClinicalTrials.gov registry entry for NCT02930044 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Early administration of subcutaneous insulin glargine dose is the first listed.
NCT02930044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02930044 about?
NCT02930044 is a clinical study titled "Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis". The purpose of this study is to determine whether adult DKA patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous (IV) insulin infusion.
What is the current status of trial NCT02930044?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-10. Estimated completion is 2021-11-01.
What interventions are being tested in trial NCT02930044?
The interventions under investigation include: Early administration of subcutaneous insulin glargine dose (OTHER), IV insulin infusion (OTHER), IV fluid repletion (DRUG).
Who is sponsoring clinical trial NCT02930044?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.